In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 351 to 372 of 372

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]	Technology appraisal guidance	11 March 2026
Venglustat for treating gangliosidoses in people 2 years and over ID 6358	Technology appraisal guidance	TBC
Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults	Interventional procedures guidance	11 September 2025
Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for extracorporeal cardiopulmonary resuscitation (ECPR) in adults in refractory cardiac arrest	Interventional procedures guidance	11 September 2025
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]	Technology appraisal guidance	TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099	Technology appraisal guidance	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]	Technology appraisal guidance	10 September 2025
Vosoritide for treating achondroplasia in people 4 months and over ID6488	Technology appraisal guidance	TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]	Highly specialised technology	TBC
Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]	Technology appraisal guidance	28 January 2026
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]	Technology appraisal guidance	22 November 2017
Women's and reproductive health guidelines	NICE guideline	TBC
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]	Technology appraisal guidance	TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]	Technology appraisal guidance	14 May 2026
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]	Technology appraisal guidance	20 August 2025
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]	Technology appraisal guidance	TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]	Technology appraisal guidance	TBC
Zio XT for detecting cardiac arrhythmias	Medical technologies guidance	TBC
Zuranolone for treating postnatal depression [ID6431]	Technology appraisal guidance	15 October 2025
⁠Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for postcardiotomy cardiogenic shock in adults	Interventional procedures guidance	11 September 2025

Results per page

10
25
50
All